SCHEMBL18701971

SCHEMBL18701971

CC(C)(C)C(=O)N1CCC1c1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 7/20 0.72
CCNC P24863 7/20 0.46
CDK8 P49336 7/20 0.46
HSD11B1 P28845 1/20 0.41
MC4R P32245 2/20 0.41
PDE5A O76074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19471151 0.84 RIPK1 (1.00) RIPK1
SCHEMBL17881870 0.84 RIPK1 (1.00) RIPK1
SCHEMBL18711673 0.82 CCNC (0.49) RIPK1CCNCCDK8HSD11B1
SCHEMBL24133812 0.76 RIPK1 (0.74) RIPK1CCNCCDK8
SCHEMBL18701984 0.76 RIPK1 (0.59) RIPK1
SCHEMBL4167780 0.76 SLC6A9 (0.51) RIPK1CCNCCDK8
SCHEMBL4160820 0.76 SLC6A9 (0.48) RIPK1
SCHEMBL22705434 0.76 RIPK1 (0.53) RIPK1CCNCCDK8HSD11B1
SCHEMBL12935925 0.75 RIPK1 (1.00) RIPK1HSD11B1
SCHEMBL20580380 0.75 RIPK1 (0.52) RIPK1CCNCCDK8HSD11B1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963462-B2 Sepiapterin reductase inhibitors MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2018-05-08 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR RIPK1 2586/4885CCNC 4598/4885CDK8 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.